Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit
ConclusionILC patients could derive significant DFS and OS benefits from CT, especially for high-risk patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Endocrine Therapy | France Health | HER2 | Hormones | Lobular Carcinoma